No abstract

were assessed according to the VARC-2 criteria. 41.4% underwent TAVI with use of a "next generation" THV. Approximately 15% of These patients developed SIRS within the first 48h after TAVI. The patients with development of SIRS showed an increased inflammatory activity already at baseline. In a ROC curve-based cut off analysis, a leukocyte count >8 G/L, CRP levels >13.3 mg/L and IL-6 levels >4.9 pg/mL were chosen to be the optimal cut-off values to identify patients who are at high risk for SIRS. Major vascular complications and acute kidney injury were associated with the occurrence of SIRS. History of stroke and the occurrence of acute kidney injury were independent predictors of SIRS. In next generation, THV patients, the occurrence of SIRS was related to 30-day-, 1-year-and 3-yearmortality (13.3% vs. 0.7%, 28.9% vs. 8.9%, and 37.8% vs. 13.0%, respectively; p<0.001). Conclusions:With "next generation" THVs, the occurrence of SIRS after TAVI could be reduced significantly, but is still associated with mortality. Most patients (76.6%) underwent TAVR through transfemoral approach with balloon-expandable (45.6%). Procedure was successful in 94.6% of the global population and in-hospital mortality rate was 7.2%. Procedural and in-hospital outcomes are summarized in Table-1. However, interaction between the TAVR and the mitral prostheses leading to valve embolization presented twice the rate in patients without PMP. The rate of bleeding and the length of stay were larger for PMP patients. P6346 | BEDSIDENo differences in the mortality rate were found but they presented a 2-fold increase in the rate of NYHA class III or IV at 1-year follow-up (20.8% vs. 10.8%, p=0.024). Background: Annually more than 200,000 patients are treated with surgical aortic valve replacement. Concern has been raised regarding the long-term durability of the Mitroflow biological heart valve prosthesis. Purpose: To assess the incidence of structural valve deterioration (SVD) for the Mitroflow bioprosthesis in a nationwide study in Denmark including all patients alive in Denmark who had received a Mitroflow aortic valve prosthesis since 2000. Methods: Patients alive in Denmark with a Mitroflow bioprosthesis implanted since January 2000 were invited to participate in a nationwide cross-sectional study with a predefined definition of SVD. A total of 1717 patients were identified, 861 were deceased, 47 had been reoperated with 40 due to SVD and 165 were operated in a private hospital or were turists. The remaining 644 patients were invited for evaluation and 574 accepted and were evaluated for SVD. Incidence of SVD was calculated using competing risks regression analysis with death as competing event.Results: With echocardiography 173 were diagnosed with SVD, of these 64 patients (11.1%) had severe SVD and 109 (19.0%) moderate SVD. Severe SVD was associated with prosthesis age and small prosthesis size (OR for a size 21 prosthesis 4.11 CIF of reoperation or severe SVD Conclusion:The incidence of undetected severe SVD was as high as the incidenc...